Table 2

Positivity of nasopharyngeal swabs for influenza virus RNA 6 days after symptom onset according to patient characteristics

Variable

N. of patients positive for

viral RNA 6 days after

symptom onset/total (%)

p valuea


Sex

Male

15/21 (71.4)

Female

13/16 (81.3)


Immunosuppressionb

Present

6/6 (100)

Absent

22/31 (71)


Underlying lung diseasec

Present

7/8 (87.5)

Absent

21/29 (72.4)


Any complicationd

0.005

Present

17/17 (100)

Absent

11/22 (50)


Any complication excluding pneumonia

Present

6/6 (100)

Absent

11/20 (55)


Pneumonia

0.02

Present

11/11 (100)

Absent

17/26 (65.4)


Antiviral treatment

Yes

21/28 (75)

No

7/9 (77.8)


Time from symptom onset to initiation of treatment

≤ 2 days

10/15 (66.7)

> 2 days

11/13 (84.6)


Antiviral treatment regimene

standard

4/5 (80)

intensified

17/23 (73.9)


Antiviral treatment duration

0.02

≤ 5 days

3/8 (37.5)

> 5 days

18/20 (90)


Antibiotic/antimycotic treatment

yes

18/20 (90)

no

10/17 (58.8)


Steroid treatment

yes

4/4 (100)

no

24/33 (72.7)


a by chi-square test; p values ≥0.05 have been omitted.

b HIV or hairy cells leukaemia.

c COPD or Asthma.

d Pneumonia, exacerbation of COPD or asthma, petechial rash, elevated ALT.

e Standard treatment: oseltamivir 75 mg twice/day; intensified treatment: increased dosage of oseltamivir or oseltamivir+zanamivir.

Meschi et al. BMC Infectious Diseases 2011 11:140   doi:10.1186/1471-2334-11-140

Open Data